Where is Medication Management Available
While injection-site irritation is well recognized, clinicians are increasingly observing broader skin changes in patients treated with semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide Read More GLP-1s and Dermatologic Reactions: Beyond Injection-Site Effects Dermatologic reactions linked to GLP-1 therapy are gaining attention as the use of glucagon-like peptide-1 receptor agonists continues to expand in diabetes and obesity care
Those findings add to hope that larger trials being run by Ozempics maker, Novo Nordisk, will be successful, Carrillo told CNN
Safety and effectiveness of longer-term phentermine use: Clinical outcomes from an electronic health record cohort, Obesity (2019) Qsymia, DailyMed (2024) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial, The Lancet (2011) Long-term drug treatment for obesity: A systematic and clinical review, JAMA (2014) Lillys Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs
